Skip to main content
Year archive

Genmab — 2018 filings

All 68 regulatory filings released by Genmab (GMAB) in 2018, sourced directly from the official regulator.

68 Filings
2018 Period
2018 filings (68)
Filing Released Lang
Regulatory Filings 2018
Regulatory Filings
2018-12-14 English
Genmab Announces Submission of Supplemental New Drug Application for Daratumumab in Front Line Multiple Myeloma in Japan
Regulatory Filings
2018-12-14 English
Director's Dealing 2018
Director's Dealing
2018-12-10 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2018-11-20 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2018-11-20 English
Legal Proceedings Report 2018
Legal Proceedings Report
2018-10-29 English
Genmab Announces Positive Topline Results in Phase III MAIA Study of Daratumumab in Front Line Multiple Myeloma
Regulatory Filings
2018-10-29 English
Regulatory Filings 2018
Regulatory Filings
2018-10-21 English
Genmab Announces Positive Topline Results in Phase III CASSIOPEIA Study of Daratumumab in Front Line Multiple Myeloma
Regulatory Filings
2018-10-21 English
Earnings Release 2018
Earnings Release Q3 2018
2018-10-16 English
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2018
Earnings Release Q3 2018
2018-10-16 English
Director's Dealing 2018
Director's Dealing
2018-10-11 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2018-09-18 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2018-09-18 English
M&A Activity 2018
M&A Activity
2018-08-31 English
Genmab Announces European Marketing Authorization for DARZALEX® (daratumumab) for Front Line Multiple Myeloma
Regulatory Filings
2018-08-31 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2018-08-14 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2018-08-14 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-08-09 English
Major Shareholder Announcement
Major Shareholding Notification
2018-08-09 English
Report Publication Announcement 2018
Report Publication Announcement H1 2018
2018-08-08 English
Genmab Announces Financial Results for the First Half of 2018
Interim / Quarterly Report H1 2018
2018-08-08 English
Legal Proceedings Report 2018
Legal Proceedings Report
2018-07-27 English
CHMP Issues Positive Opinion Recommending DARZALEX® (daratumumab) for Front Line Multiple Myeloma
Regulatory Filings
2018-07-27 English
Earnings Release 2018
Earnings Release Q2 2018
2018-07-17 English
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2018
Earnings Release Q2 2018
2018-07-17 English
Regulatory Filings 2018
Regulatory Filings
2018-07-12 English
Genmab Enters Strategic Partnership with Immatics to Discover and Develop Next Generation Bispecific Cancer Immunotherapies
Regulatory Filings
2018-07-12 English
Director's Dealing 2018
Director's Dealing
2018-07-03 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2018-07-03 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2018-07-03 English
Regulatory Filings 2018
Regulatory Filings
2018-06-29 English
HuMax®-AXL-ADC Progress Triggers Milestone Payment to Seattle Genetics
Regulatory Filings
2018-06-29 English
Regulatory Filings 2018
Regulatory Filings
2018-05-26 English
Genmab Announces that Janssen Will Stop Studies of Daratumumab in Combination with Anti-PD-(L)1
Regulatory Filings
2018-05-26 English
Regulatory Filings 2018
Regulatory Filings
2018-05-24 English
Genmab Announces Topline Results in Phase III study of Arzerra® in Indolent Non-Hodgkin’s Lymphoma
Regulatory Filings
2018-05-24 English
Director's Dealing 2018
Director's Dealing
2018-05-18 English
Director's Dealing 2018
Director's Dealing
2018-05-16 English
Director's Dealing 2018
Director's Dealing
2018-05-15 English
Director's Dealing 2018
Director's Dealing
2018-05-15 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2018-05-15 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2018-05-15 English
Regulatory Filings 2018
Regulatory Filings
2018-05-08 English
Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Newly Diagnosed Multiple Myeloma
Regulatory Filings
2018-05-08 English
Earnings Release 2018
Earnings Release Q1 2018
2018-04-17 English
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2018
Earnings Release Q1 2018
2018-04-17 English
Regulatory Filings 2018
Regulatory Filings
2018-04-13 English
Director's Dealing 2018
Director's Dealing
2018-04-04 English
Director's Dealing 2018
Director's Dealing
2018-04-03 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2018-04-03 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2018-04-03 English
Director's Dealing 2018
Director's Dealing
2018-04-03 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change
2018-02-28 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Regulatory Filings
2018-02-28 English
Annual Report 2017
Annual Report FY 2017
2018-02-21 English
Annual Report 2017
Annual Report FY 2017
2018-02-21 English
Genmab 2017 Annual Report
Regulatory Filings
2018-02-21 English
Genmab 2017 Annual Report
Report Publication Announcement
2018-02-21 English
Earnings Release 2017
Earnings Release FY 2017
2018-01-23 English
Genmab Announces 2017 Net Sales Figures for DARZALEX® (Daratumumab)
Earnings Release FY 2017
2018-01-23 English
Regulatory Filings 2018
Regulatory Filings
2018-01-22 English
Genmab Announces Novartis’ Intention to Transition Arzerra® (ofatumumab) from Commercial Availability to Limited Availability via Compassionate Use Programs for the Treatment of CLL in Non-US Markets
Regulatory Filings
2018-01-22 English
Regulatory Filings 2018
Regulatory Filings
2018-01-19 English
U.S. FDA Grants Priority Review for Daratumumab in Front Line Multiple Myeloma
Regulatory Filings
2018-01-19 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-01-09 English
Major Shareholder Announcement
Regulatory Filings
2018-01-09 English
Director's Dealing 2018
Director's Dealing
2018-01-02 English